AcroViz

AcroViz is a Taiwan-based brain health company developing and commercializing AI-enabled imaging biomarkers derived from diffusion MRI. Its core offering, Axonal Brain Age, analyzes brain white-matter microstructure to generate quantitative assessments of brain health and estimate dementia-related risk. The company positions its technology for early detection, longitudinal monitoring, and clinical decision support in neurodegenerative and neuropsychiatric conditions. AcroViz works at the intersection of medical imaging, machine learning, and digital diagnostics rather than drug development, and appears focused on clinical deployment and validation of brain-age-based assessment tools.